MeSH tree: D12.125.072.050.685.400.500
Dopamine in the brain influences movement, learning, motivation and sleep. In humans, problems with dopamine are linked to conditions like Parkinson's disease, depression and sleep disorders. While scientists know a great ...
Jan 13, 2026
0
41
Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the striatum may improve the efficacy of a first-line therapy for Parkinson's disease and has the potential ...
Jan 5, 2026
0
38
A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how scientists think about Parkinson's disease treatments.
Dec 17, 2025
0
64
The age-old advice to "trust your gut" could soon take on new meaning for people diagnosed with Parkinson's disease, thanks to a creative feat of bioengineering by researchers in the University of Georgia's College of Veterinary ...
Nov 17, 2025
0
80
The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people with the disease more control over their movements.
Oct 29, 2025
0
7
A research team from the University of Cologne conducted one of the most comprehensive studies on dopamine and decision-making in humans so far, providing evidence for effects of the former on the latter. Dopamine is a neurotransmitter ...
Oct 28, 2025
0
0
Detecting early rising Parkinson's disease (PD) symptoms could improve treatment outcomes by enabling earlier treatment interventions. In a new eNeuro paper, Daniil Berezhnoi, from Georgetown University, and colleagues used ...
Jul 28, 2025
0
0
A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets.
Jul 11, 2025
0
10
Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to treat Parkinson's disease.
Jun 26, 2025
0
47
For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time versus placebo, according to a ...
Apr 8, 2025
0
1
